AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11032589 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen 20 mg/d (ER-positive subgroup)
Number of subjects: 899
Study 8955551 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-forms of WAIS-R
Number of subjects: 624
Study 8955551 — intervention group
Group type: EXPERIMENTAL
Intervention: Six- and seven-subtest short-forms
Number of subjects: 624
Study 1740538 — intervention group
Group type: COMPARATOR
Intervention: HCTZ/TRI (25 mg/50 mg)
Number of subjects: 256
Study 1740538 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 25 mg (Ate-25)
Number of subjects: 256
Study 1740538 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50 mg (Ate-50)
Number of subjects: 256
Study 1740538 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 25 mg + HCTZ/TRI (Ate-25/HCTZ/TRI)
Number of subjects: 256
Study 1740538 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg + HCTZ/TRI (Ate-50/HCTZ/TRI)
Number of subjects: 256
Study 1740538 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 25 mg (Ate-25), Atenolol 50 mg (Ate-50), HCTZ/TRI, Ate-25/HCTZ/TRI, Ate-50/HCTZ/TRI
Number of subjects: 256
Study 1740538 — intervention group
Group type: EXPERIMENTAL
Intervention: HCTZ/TRI (25 mg/50 mg), Ate-25/HCTZ/TRI, Ate-50/HCTZ/TRI
Number of subjects: 256
Study 6747020 — intervention group
Group type: EXPERIMENTAL
Intervention: wax‐matrix KCl
Number of subjects: 90
Study 6747020 — intervention group
Group type: EXPERIMENTAL
Intervention: microencapsulated KCl
Number of subjects: 90
Study 6747020 — intervention group
Group type: EXPERIMENTAL
Intervention: liquid KCl
Number of subjects: 90
Study 6747020 — intervention group
Group type: EXPERIMENTAL
Intervention: experimental extended‐release capsules
Number of subjects: 90
Study 6747020 — intervention group
Group type: EXPERIMENTAL
Intervention: experimental extended‐release tablets
Number of subjects: 90
Study 6747020 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 90
Study 31033228 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load resistance training (30% 1RM) with partial blood-flow restriction training (BFRT)
Number of subjects: 48
Study 31033228 — intervention group
Group type: EXPERIMENTAL
Intervention: High-load resistance training (HL-RT; 70% 1 repetition maximum [1RM])
Number of subjects: 48
Study 31033228 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study 31022213 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin (40 IU once daily for four weeks)
Number of subjects: 16
Study 31022213 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline once daily for four weeks)
Number of subjects: 16
Study 27739334 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-referral to inpatient treatment (SRIT)
Number of subjects: 54
Study 27739334 — intervention group
Group type: COMPARATOR
Intervention: Treatment As Usual (TAU)
Number of subjects: 54
Study 25214387 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-set (MS) resistance training
Number of subjects: 11
Study 25214387 — intervention group
Group type: EXPERIMENTAL
Intervention: Tri-set (TS) resistance training
Number of subjects: 11
Study 24631983 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-controlled ventilation (PCV)
Number of subjects: 40
Study 24631983 — intervention group
Group type: COMPARATOR
Intervention: Volume-controlled ventilation (VCV)
Number of subjects: 40
Study 22464408 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OC)
Number of subjects: 703
Study 22464408 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate (DMPA)
Number of subjects: 703
Study 22464408 — intervention group
Group type: COMPARATOR
Intervention: Nonhormonal (NH) birth control
Number of subjects: 703
Study 22464408 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal contraception (OC and DMPA)
Number of subjects: 703
Study 20709667 — intervention group
Group type: EXPERIMENTAL
Intervention: NMSG 4/90
Number of subjects: 1271
Study 20709667 — intervention group
Group type: EXPERIMENTAL
Intervention: NMSG 5/94
Number of subjects: 1271
Study 20709667 — intervention group
Group type: EXPERIMENTAL
Intervention: NMSG 7/98
Number of subjects: 1271
Study 20709667 — intervention group
Group type: COMPARATOR
Intervention: Swedish patients
Number of subjects: 1271
Study 20709667 — intervention group
Group type: EXPERIMENTAL
Intervention: Danish patients
Number of subjects: 1271
Study 18232242 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced Illness Care Teams (AICTs)
Number of subjects: 118
Study 18232242 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 118
Study 15860827 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral supplementation using 1000 mg calcium with 800 IU cholecalciferol and information leaflet on dietary calcium intake and prevention of falls
Number of subjects: 3314
Study 15860827 — intervention group
Group type: COMPARATOR
Intervention: Leaflet only (control group)
Number of subjects: 3314
Study 15515549 — intervention group
Group type: EXPERIMENTAL
Intervention: bFGF injected into tympanic cavity
Number of subjects: 40
Study 9685824 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted diagnosis (CAD) system
Number of subjects: 120
Study 9685824 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening radiologist with CAD
Number of subjects: 120
Study 9685824 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical radiologist with CAD
Number of subjects: 120
Study 9685824 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert screener
Number of subjects: 120
Study 9685824 — intervention group
Group type: COMPARATOR
Intervention: Screening radiologist without CAD
Number of subjects: 120
Study 9685824 — intervention group
Group type: COMPARATOR
Intervention: Clinical radiologist without CAD
Number of subjects: 120
Study 8017639 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 36
Study 8017639 — intervention group
Group type: COMPARATOR
Intervention: AVP type V1 antagonist (AVPA)
Number of subjects: 36
Study 8017639 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (1.25 mg intravenous)
Number of subjects: 36
Study 8017639 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (1.25 mg intravenous) + AVPA (0.5 mg)
Number of subjects: 36
Study 8017639 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular lidocaine (control)
Number of subjects: 36
Study 2642789 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled anastomoses
Number of subjects: 73
Study 2642789 — intervention group
Group type: COMPARATOR
Intervention: Sutured anastomoses
Number of subjects: 73
Study 1066224 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetics (3.6 ml submucous injection)
Number of subjects: 8
Study 1066224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30664012 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of 0.2% levobupivacaine (5 ml/h)
Number of subjects: 70
Study 30664012 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed intermittent bolus infusion of 0.2% levobupivacaine (15 ml every 3h)
Number of subjects: 70
Study 30664012 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed intermittent bolus infusion of 0.2% levobupivacaine
Number of subjects: 70
Study 30664012 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of 0.2% levobupivacaine
Number of subjects: 70
Study 28400355 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-I delivered via the Sleepcare mobile phone app
Number of subjects: 151
Study 28400355 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 151
Study 25932549 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab 0.16 mg/0.05 mL
Number of subjects: 62
Study 25932549 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 62
Study 23798671 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 25 mg once daily for 5 days
Number of subjects: 80
Study 23798671 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 80
Study 21730219 — intervention group
Group type: EXPERIMENTAL
Intervention: High-GL meals
Number of subjects: 10
Study 21730219 — intervention group
Group type: EXPERIMENTAL
Intervention: High-GI meals
Number of subjects: 10
Study 21730219 — intervention group
Group type: COMPARATOR
Intervention: Low-GL meals
Number of subjects: 10
Study 21730219 — intervention group
Group type: COMPARATOR
Intervention: Low-GI meals
Number of subjects: 10
Study 21730219 — intervention group
Group type: COMPARATOR
Intervention: Cortisol responses
Number of subjects: 10
Study 21730219 — intervention group
Group type: COMPARATOR
Intervention: GI × GL interactions
Number of subjects: 10
Study 21730219 — intervention group
Group type: COMPARATOR
Intervention: Effect modification by gender
Number of subjects: 10
Study 19891018 — intervention group
Group type: EXPERIMENTAL
Intervention: CO(2) insufflation
Number of subjects: 120
Study 19891018 — intervention group
Group type: COMPARATOR
Intervention: Standard air insufflation
Number of subjects: 120
Study 17023279 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative multiple-injection thoracic paravertebral blocks (PVB group, n = 25)
Number of subjects: 50
Study 17023279 — intervention group
Group type: COMPARATOR
Intervention: Preoperative multiple subcutaneous saline injections (Control group, n = 25)
Number of subjects: 50
Study 12742881 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment and referral (A/R) at every visit (every 2 months)
Number of subjects: 0
Study 12742881 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment and referral (A/R) every 6 months
Number of subjects: 0
Study 12742881 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment and referral (A/R) every visit to children found to be behind at 8 months of age
Number of subjects: 0
Study 12742881 — intervention group
Group type: COMPARATOR
Intervention: Control group (no A/R)
Number of subjects: 0
Study 10705321 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet use (300 mm Hg)
Number of subjects: 120
Study 10705321 — intervention group
Group type: COMPARATOR
Intervention: No tourniquet use
Number of subjects: 120
Study 9337499 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral treatment (voucher incentive program and community reinforcement approach)
Number of subjects: 39
Study 9337499 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (lifestyle counseling)
Number of subjects: 39
Study 7940610 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultured epidermal allografts
Number of subjects: 0
Study 7940610 — intervention group
Group type: COMPARATOR
Intervention: Untreated identical wounds
Number of subjects: 0
Study 3527305 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (AG) 1.000 mg/day with hydrocortisone (HC) 20‐40 mg/day
Number of subjects: 338
Study 3527305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 338
Study 30661672 — intervention group
Group type: EXPERIMENTAL
Intervention: Permissive underfeeding
Number of subjects: 55
Study 30661672 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 55
Study 30022252 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% autologous serum drops (ASD)
Number of subjects: 50
Study 30022252 — intervention group
Group type: COMPARATOR
Intervention: Conventional artificial tears (CAT)
Number of subjects: 50
Study 27567350 — intervention group
Group type: EXPERIMENTAL
Intervention: DHAKA score
Number of subjects: 496
Study 27567350 — intervention group
Group type: COMPARATOR
Intervention: IMCI algorithm
Number of subjects: 496
Study 24906582 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment as usual plus yoga
Number of subjects: 18
Study 24906582 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual only
Number of subjects: 18
Study 21833588 — intervention group
Group type: EXPERIMENTAL
Intervention: Three cycles of 75 mg/m² cisplatin plus 75 mg/m² docetaxel, followed by three cycles of 1,200 mg/m² gemcitabine (arm A)
Number of subjects: 88
Study 21833588 — intervention group
Group type: COMPARATOR
Intervention: Three cycles of 25 mg/m² cisplatin plus 25 mg/m² docetaxel, followed by three cycles of 1,200 mg/m² gemcitabine (arm B)
Number of subjects: 88
Study 19391537 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 139
Study 19391537 — intervention group
Group type: COMPARATOR
Intervention: TENS
Number of subjects: 139
Study 17466852 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical indomethacin 4 times daily for 3 days preoperatively and 1 month postoperatively
Number of subjects: 179
Study 17466852 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical indomethacin 4 times daily for 1 month postoperatively
Number of subjects: 179
Study 17466852 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving only topical steroids and antibiotics
Number of subjects: 179
Study 17466852 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical indomethacin preoperatively
Number of subjects: 179
Study 17466852 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical indomethacin postoperatively
Number of subjects: 179
Study 16326294 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical valdecoxib
Number of subjects: 53
Study 16326294 — intervention group
Group type: COMPARATOR
Intervention: Liquid paraffin (Control)
Number of subjects: 53
Study 12176795 — intervention group
Group type: EXPERIMENTAL
Intervention: RPR 109881A (1-hour infusion)
Number of subjects: 63
Study 12176795 — intervention group
Group type: EXPERIMENTAL
Intervention: RPR 109881A (3-hour infusion)
Number of subjects: 63
Study 9447850 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (0, 5, or 10 mg intravenously before induction of anesthesia and every 12 h after operation until the patient could take oral medications; 0, 50, or 100 mg orally once a day as specified by blood pressure and heart rate)
Number of subjects: 200
Study 9447850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 7545256 — intervention group
Group type: EXPERIMENTAL
Intervention: P-glycoprotein (P-gly) staining in AFP-producing gastric cancers
Number of subjects: 40
Study 7545256 — intervention group
Group type: EXPERIMENTAL
Intervention: P-gly positivity in AFP-positive cases
Number of subjects: 40
Study 7545256 — intervention group
Group type: EXPERIMENTAL
Intervention: P-gly expression in diploid tumors
Number of subjects: 40
Study 7545256 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings regarding P-gly in AFP producing gastric carcinoma
Number of subjects: 40
Study 2576322 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (10 mg/kg)
Number of subjects: 32
Study 2576322 — intervention group
Group type: COMPARATOR
Intervention: Neuroleptic treatment
Number of subjects: 32
Study 776538 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysometra (2.5 ml intramuscular injections for three 20-day courses)
Number of subjects: 200
Study 776538 — intervention group
Group type: COMPARATOR
Intervention: Methylandrostendiol (5 mg intramuscular injections for three 20-day courses)
Number of subjects: 200
Study 31050109 — intervention group
Group type: EXPERIMENTAL
Intervention: iGlarLixi 5 U/5 μg
Number of subjects: 20
Study 31050109 — intervention group
Group type: EXPERIMENTAL
Intervention: iGlarLixi 10 U/10 μg
Number of subjects: 20
Study 31050109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31050109 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine 5 U
Number of subjects: 20
Study 28963150 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic-on-metal (CoM)
Number of subjects: 67
Study 28963150 — intervention group
Group type: COMPARATOR
Intervention: Metal-on-metal (MoM)
Number of subjects: 67
Study 25408222 — intervention group
Group type: EXPERIMENTAL
Intervention: Macushield (10 mg meso‐zeaxanthin, 10 mg lutein, 2 mg zeaxanthin)
Number of subjects: 31
Study 25408222 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sunflower oil)
Number of subjects: 31
Study 23338109 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 3 mg/kg with Nitroglycerin 200 µg
Number of subjects: 40
Study 23338109 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 3 mg/kg
Number of subjects: 40
Study 20628825 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP (mean pressure, 16.4 cm H(2)O)
Number of subjects: 12
Study 20628825 — intervention group
Group type: COMPARATOR
Intervention: APAP (ResMed S8 Autoset II)
Number of subjects: 12
Study 20628825 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 12
Study 20628825 — intervention group
Group type: COMPARATOR
Intervention: APAP
Number of subjects: 12
Study 20628825 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP and APAP
Number of subjects: 12
Study 18314091 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory ergonomic intervention process
Number of subjects: 59
Study 16446342 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin plus vinorelbine and cisplatin (arm A)
Number of subjects: 120
Study 16446342 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine and cisplatin alone (placebo patch, arm B)
Number of subjects: 120
Study 15644588 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 47
Study 15644588 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin (20 mg/day)
Number of subjects: 47
Study 11694666 — intervention group
Group type: EXPERIMENTAL
Intervention: Cod liver oil (n-3 long-chain PUFAs)
Number of subjects: 590
Study 11694666 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (n-6 long-chain PUFAs)
Number of subjects: 590
Study 9466165 — intervention group
Group type: EXPERIMENTAL
Intervention: RS-8359
Number of subjects: 0
Study 9466165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9466165 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 0
Study 9466165 — intervention group
Group type: EXPERIMENTAL
Intervention: RS-8359 (multiple doses)
Number of subjects: 0
Study 9466165 — intervention group
Group type: EXPERIMENTAL
Intervention: RS-8359 (single dose)
Number of subjects: 0
Study 8187308 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 micrograms lanreotide
Number of subjects: 4
Study 8187308 — intervention group
Group type: COMPARATOR
Intervention: 150 micrograms octreotide
Number of subjects: 4
Study 8187308 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg lanreotide (SR-L)
Number of subjects: 4
Study 8187308 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term treatment with SR-L (2-3 injections/month for 3-6 months)
Number of subjects: 4
Study 3034318 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg once daily
Number of subjects: 25
Study 3034318 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 25 mg once daily
Number of subjects: 25
Study 3034318 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg + HCTZ 25 mg once daily
Number of subjects: 25
Study 3034318 — intervention group
Group type: EXPERIMENTAL
Intervention: HCTZ 25 mg + Captopril 50 mg once daily
Number of subjects: 25
Study 29066219 — intervention group
Group type: EXPERIMENTAL
Intervention: One bag system
Number of subjects: 30
Study 29066219 — intervention group
Group type: COMPARATOR
Intervention: Two bag system
Number of subjects: 30
Study 26160226 — intervention group
Group type: EXPERIMENTAL
Intervention: Planning intervention
Number of subjects: 506
Study 26160226 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy intervention
Number of subjects: 506
Study 26160226 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 506
Study 25595413 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic spinal manipulative therapy (SMT)
Number of subjects: 45
Study 25595413 — intervention group
Group type: COMPARATOR
Intervention: Sham thoracic SMT
Number of subjects: 45
Study 25595413 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Thoracic SMT and Sham SMT)
Number of subjects: 45
Study 22968743 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with documented CAD
Number of subjects: 4133
Study 22968743 — intervention group
Group type: COMPARATOR
Intervention: Patients without documented CAD
Number of subjects: 4133
Study 19819530 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg and standard analgesia (tylenol with codeine)
Number of subjects: 78
Study 19819530 — intervention group
Group type: COMPARATOR
Intervention: Standard analgesia only
Number of subjects: 78
Study 18154772 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 250
Study 18154772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 15947595 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening arm (Prostate specific antigen testing, digital rectal examination, transrectal ultrasound, sextant biopsies)
Number of subjects: 35148
Study 15947595 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no specific intervention mentioned, only yearly linkage with the Rotterdam Cancer Registry)
Number of subjects: 35148
Study 14638545 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal insufficiency (CrCl ≤60 mL/min)
Number of subjects: 2082
Study 11409184 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral doxofylline (400 mg BID)
Number of subjects: 14
Study 11409184 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 14
Study 8900084 — intervention group
Group type: EXPERIMENTAL
Intervention: Coming Out Issues Group (10-week educational-experiential group intervention)
Number of subjects: 0
Study 1899136 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel IUD (20 micrograms daily)
Number of subjects: 2758
Study 1899136 — intervention group
Group type: COMPARATOR
Intervention: Copper-releasing IUD (Nova-T)
Number of subjects: 2758
Study 6355069 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 0
Study 6355069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31340528 — intervention group
Group type: COMPARATOR
Intervention: Coaching group
Number of subjects: 288
Study 31340528 — intervention group
Group type: COMPARATOR
Intervention: Coaching and SMS group
Number of subjects: 288
Study 28612894 — intervention group
Group type: EXPERIMENTAL
Intervention: iProcto consultation (group A)
Number of subjects: 126
Study 28612894 — intervention group
Group type: COMPARATOR
Intervention: Regular consultation (group B)
Number of subjects: 126